The data suggest that co-existing cardiovascular disease and immunologic disruptions, such as insulin receptor autoantibodies, may serve as predictive indicators of poor therapeutic response and should be considered in future efforts to optimize precision-based diabetes management. This evidence concerns the gene INSR and diabetes mellitus.